Budesonide plus prevacid (DrugBank: Budesonide)
9 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
66 | IgA nephropathy | 0 |
93 | Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)] | 0 |
94 | Primary sclerosing cholangitis | 0 |
95 | Autoimmune hepatitis | 0 |
96 | Crohn disease | 0 |
97 | Ulcerative colitis | 0 |
98 | Eosinophilic gastrointestinal disease | 1 |
228 | Bronchiolitis obliterans | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00638456 (ClinicalTrials.gov) | February 2008 | 12/3/2008 | Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis | Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial | Eosinophilic Esophagitis | Drug: Budesonide plus Prevacid;Drug: placebo plus Prevacid | Ranjan Dohil | Meritage Pharma, Inc. | Completed | 1 Year | N/A | All | 32 | Phase 2 | United States |